Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

DataM Intelligence | competitive Intelligence Explore the evolving Multiple Myeloma market: drug innovations, emerging therapies, and key p ...

Regeneron Pharmaceuticals ... with other cancer treatments in patients with relapsed/refractory (R/R) multiple myeloma (MM). Results presented that linvoseltamab in combination with carfilzomib ...

Lynozyfic’s global sales are projected to reach $707 million by 2031.

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its linvoseltamab drug candidate.

and Pfizer’s Elrexfio (elranatamab), which have both been cleared by the FDA for relapsed or refractory multiple myeloma. The top-line efficacy data with Regeneron’s drug looks a little ...

Among patients who received four-drug consolidation therapy ... "Another question is how do we apply the MIDAS data to high-risk multiple myeloma?" Lentzsch continued. "Only a very small ...

CHICAGO -- Patients with undetectable disease after induction therapy for newly diagnosed multiple ... myeloma (NDMM) did not have significantly better outcomes with a stem-cell transplant versus ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...